Increase in adoption of Medtronic plc‘s MDT globally-accepted advanced therapies is encouraging. The stock currently carries a Zacks Rank #3 (Hold).

Over the past three months, Medtronic has outperformed the industry. As per the last share-price movement, the stock has gained 5.5% as against the industry’s 1.5% depreciation.

Medtronic’s fourth-quarter fiscal 2021 earnings and revenues were both ahead of the respective Zacks Consensus Estimate. According to the company, most of the end markets are returning to near-normal pre-COVID growth. While some regions are still lagging due to the prevailing health crisis, momentum built strongly throughout the fourth quarter.

Medtronic’s fiscal fourth-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in April 2020. The company continued to gain share in an increasing number of businesses, driven by…

Read more…


Comments are closed.